NCT06008379View on ClinicalTrials.gov

A Study of 7MW3711 in Subjects With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

August 30, 2025

Study Completion Date

January 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

7MW3711 for injection

IV administration of 7MW3711, Q3W, 3 weeks a cycle

DRUG

7MW3711 for injection

IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1

Trial Locations (5)

221009

NOT_YET_RECRUITING

Xuzhou Central Hospital, Xuzhou

310000

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

2000043

RECRUITING

The Lung Cancer Center of Shanghai Chest Hospital, Shanghai

Unknown

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY